Study identifier:D9690C00005
ClinicalTrials.gov identifier:NCT06450197
EudraCT identifier:N/A
CTIS identifier:2023-510487-12-00
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohn’s Disease
Moderate to severe Crohn’s disease
Phase 2
No
AZD7798
All
192
Interventional
18 Years - 80 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD7798 AZD7798 | Drug: AZD7798 AZD7798 |
Placebo Comparator: Placebo Placebo | Other: Placebo Placebo |